Dose optimization of piperacillin/tazobactam, cefepime, and ceftazidime for carbapenem-resistant Pseudomonas aeruginosa isolates in Turkiye

被引:0
作者
Buyukyanbolu, Ecem [1 ,2 ]
Gill, Christian M. [2 ]
Genc, Leyla [1 ]
Karakus, Mehmet [3 ]
Comert, Fusun [4 ]
Otlu, Baris [5 ]
Aktas, Elif [1 ]
Nicolau, David P. [2 ]
机构
[1] Univ Hlth Sci, Hamidiye Etfal Training & Res Hosp, Dept Med Microbiol, Istanbul, Turkiye
[2] Hartford Hosp, Ctr Antiinfect Res & Dev, 80 Seymour St, Hartford, CT 06102 USA
[3] Univ Hlth Sci, Dept Med Microbiol, Istanbul, Turkiye
[4] Bulent Ecevit Univ, Fac Med, Dept Med Microbiol, Zonguldak, Turkiye
[5] Inonu Univ, Fac Med, Dept Med Microbiol, Malatya, Turkiye
关键词
P; aeruginosa; Dose optimization; Cephalosporin; PK/PD; Carbapenem resistance; IN-VIVO EFFICACY; DOSING INTERVALS; THIGH-INFECTION; BETA-LACTAM; INFUSION; PHARMACODYNAMICS; PNEUMONITIS; MEROPENEM; IMIPENEM; OUTCOMES;
D O I
10.1007/s10096-024-04990-w
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction Although CRPA may test susceptible to other beta-lactams such as ceftazidime (CAZ), cefepime (FEP), and piperacillin/tazobactam (TZP), reduced potency has been observed. We assessed the adequacy of EUCAST Susceptible (S) or Susceptible Increased Exposure (SIE)/(I) doses for CAZ, FEP, and TZP against CRPA clinical isolates. Methods CRPA isolates were collected from patients at three Turkish hospitals. CAZ, FEP, and TZP MICs were determined using broth microdilution. Monte Carlo simulations were performed to determine the probability of target attainment (PTA) for a free time above the MIC (fT > MIC) targets for various doses of each agent against isolates defined as susceptible. fT > MIC targets were 70% for CAZ or FEP and 50% for TZP. Cumulative fraction of response (CFR) was calculated. Optimal PTA and CFR was 90% target achievement. Results The percentages of isolates SIE/I to CAZ, FEP, and TZP were 49,8%, 47%, and 31,8% respectively. Reduced potency was noted with 54,1% of CAZ-S isolates having MICs of 4 or 8 mg/L. Of the FEP and TZP-S isolates, MICs at the breakpoint (8 and 16 mg/L, respectively) were the mode with 45,2 and 53,9% of isolates for each, respectively. At an MIC of 8 mg/L for CAZ, the EUCAST standard dose was insufficient (CFR of 85%). 3 h infusions of EUCAST SIE doses were required for 90% PTA at MIC of 8 mg/L and an optimized CFR of 100%. For FEP, the SIE dose of 2 g q8h 0.5 h infusion of was effective (CFR 96%), utilization of an extended 3 h infusion further optimized the PTA at 8 mg/L (CFR 99%). For TZP, the standard dose of 4.5 q6h administered as a 0.5 h infusion was inadequate (CFR 86%). A standard TZP dose with an extended infusion (4.5 g q8h over 4 h) and the SIE dose 4.5 g q6h 3 h infusion resulted in CFRs > 95%. Conclusion These data support the EUCAST SIE breakpoints for FEP and TZP. To optimize PTA at the SIE breakpoint for CAZ, prolonged infusion is required.
引用
收藏
页码:159 / 165
页数:7
相关论文
共 50 条
[31]   Mechanisms of resistance in clinical isolates of Pseudomonas aeruginosa less susceptible to cefepime than to ceftazidime [J].
Esquisabel, A. B. Campo ;
Rodriguez, M. C. ;
Campo-Sosa, A. O. ;
Rodriguez, C. ;
Martinez-Martinez, L. .
CLINICAL MICROBIOLOGY AND INFECTION, 2011, 17 (12) :1817-1822
[32]   Phenotypic and Molecular Detection of the Metallo-Beta-Lactamases in Carbapenem-Resistant Pseudomonas aeruginosa Isolates from Clinical Samples [J].
Vural, Elif ;
Delialioglu, Nuran ;
Ulger, Seda Tezcan ;
Emekdas, Gurol ;
Serin, Mehmet Sami .
JUNDISHAPUR JOURNAL OF MICROBIOLOGY, 2020, 13 (02)
[33]   Characteristics of rare ST463 carbapenem-resistant Pseudomonas aeruginosa clinical isolates from blood [J].
Zhang, Xiaodong ;
Tang, Miran ;
Xu, Ye ;
Xu, Mengxin ;
Qian, Changrui ;
Zheng, Xiangkuo ;
Zhou, Tieli ;
Wu, Qing .
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2023, 32 :122-130
[34]   Molecular Analysis of Antibiotic Resistance in Carbapenem-Resistant Pseudomonas aeruginosa Isolates Isolated from Clinical Samples [J].
Altan, Gulsah ;
Rakici, Erva ;
Ozgumus, Osman Birol .
MIKROBIYOLOJI BULTENI, 2024, 58 (02) :148-170
[35]   Classification of the metallo 13-lactamase subtype produced by the carbapenem-resistant Pseudomonas aeruginosa isolates in Japan [J].
Nakayama, Ryo ;
Inoue-Tsuda, Megumi ;
Matsui, Hidehito ;
Ito, Tamaki ;
Hanaki, Hideaki .
JOURNAL OF INFECTION AND CHEMOTHERAPY, 2022, 28 (02) :170-175
[36]   Carbapenem-resistant and cephalosporin-susceptible: a worrisome phenotype among Pseudomonas aeruginosa clinical isolates in Brazil [J].
Campana, Eloiza Helena ;
Xavier, Danilo Elias ;
Petrolini, Fernanda Villas-Boas ;
Cordeiro-Moura, Jhonatha Rodrigo ;
Elmor de Araujo, Maria Rita ;
Gales, Ana Cristina .
BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2017, 21 (01) :57-62
[37]   Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single Definitive Therapy for Pseudomonas aeruginosa Bloodstream Infection: A Multisite Retrospective Study [J].
Babich, Tanya ;
Naucler, Pontus ;
Karlsson Valik, John ;
Giske, Christian G. ;
Benito, Natividad ;
Cardona, Ruben ;
Rivera, Alba ;
Pulcini, Celine ;
Fattah, Manal Abdel ;
Haquin, Justine ;
Macgowan, Alasdair ;
Grier, Sally ;
Gibbs, Julie ;
Chazan, Bibiana ;
Yanovskay, Anna ;
Ben Ami, Ronen ;
Landes, Michal ;
Nesher, Lior ;
Zaidman-Shimshovitz, Adi ;
McCarthy, Kate ;
Paterson, David L. ;
Tacconelli, Evelina ;
Buhl, Michael ;
Mauer, Susanna ;
Rodriguez-Bano, Jesus ;
Morales, Isabel ;
Oliver, Antonio ;
De Gopegui, Enrique Ruiz ;
Cano, Angela ;
Machuca, Isabel ;
Gozalo-Marguello, Monica ;
Martinez Martinez, Luis ;
Gonzalez-Barbera, Eva M. ;
Gomez Alfaro, Iris ;
Salavert, Miguel ;
Beovic, Bojana ;
Saje, Andreja ;
Mueller-Premru, Manica ;
Pagani, Leonardo ;
Vitrat, Virginie ;
Kofteridis, Diamantis ;
Zacharioudaki, Maria ;
Maraki, Sofia ;
Weissman, Yulia ;
Paul, Mical ;
Dickstein, Yaakov ;
Leibovici, Leonard ;
Yahav, Dafna .
CLINICAL INFECTIOUS DISEASES, 2020, 70 (11) :2270-2280
[38]   Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis [J].
Kuti, Joseph L. ;
Pettit, Rebecca S. ;
Neu, Natalie ;
Cies, Jeffrey J. ;
Lapin, Craig ;
Muhlebach, Marianne S. ;
Novak, Kimberly J. ;
Nguyen, Sean T. ;
Saiman, Lisa ;
Nicolau, David P. .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2015, 83 (01) :53-55
[39]   Challenges of Carbapenem-resistant Pseudomonas aeruginosa in Infection Control and Antibiotic Management [J].
Kim, Young Jin ;
Huh, Hee Jae ;
Sung, Heungsup .
ANNALS OF LABORATORY MEDICINE, 2024, 44 (01) :1-2
[40]   Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa [J].
Shigemi, Akari ;
Matsumoto, Kazuaki ;
Yaji, Keiko ;
Shimodozono, Yoshihiro ;
Takeda, Yasuo ;
Miyanohara, Hiroaki ;
Kawamura, Hideki ;
Orita, Michiyo ;
Tokuda, Koichi ;
Nishi, Junichiro ;
Yamada, Katsushi .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2009, 34 (06) :589-591